18F-fluoride PET as a non-invasive imaging biomarker for determining treatment efficacy of bone active agents at the hip: A prospective, randomised, controlled clinical study
Journal of Bone and Mineral Research, 02/22/2013Frost ML et al.
The aim of this study was to determine if 18F–PET can be used as an early biomarker of treatment efficacy at the hip. Changes in BMD and bone turnover markers were consistent with previous trials of teriparatide. In conclusion, this is the first study demonstrating that 18F–PET can be used as an imaging biomarker for determining treatment efficacy at the hip as early as 12–weeks following initiation of therapy.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.